TY - JOUR T1 - Monitoring therapy effects of adoptive T-cell transfer in a murine model of gastric carcinoma with F18-FDG-PET JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 1581 LP - 1581 VL - 50 IS - supplement 2 AU - Mona Mustafa AU - Robert Kammerer AU - Sebastian Nowak AU - Guido Boening AU - P Bartenstein AU - Wolfgang Zimmermann Y1 - 2009/05/01 UR - http://jnm.snmjournals.org/content/50/supplement_2/1581.abstract N2 - 1581 Objectives We are presenting a CEACAM5 Promoter/SV40 T Antigen C57BL/6 mouse line, developing a solid and uniform tumor in the pyloric region of the stomach with 100% genetic penetrance. Aim of this study was the characterization of tumor growth in a control group (n=16) and an adoptive T-cell therapy group (n=8, 2 arms). Methods 10-15 MBq F18-FDG were injected i.v. into isoflurane-anesthetized, fasted, warmed mice, 30 min acquisitions 45 min p.i. (list-mode, 6min Tx-scan), 2D-OSEM reconstruction (128x128 matrix). VOIs around the tumor were created using a 60% of SUV max. threshold, reference VOIs were skeletal muscle (forepaw) and total body. Tumor volume (TV) was recorded in mm3, FDG-uptake in Bq/ml. T-cell transfer was performed on day of life 50 and 70 using T-cells of a wildtype-donor (n=4) and of a CEACAM1-deficient knockout-donor (n=4). Results TV in controls increased between day 40 and 105 by factor 10.8±1,6. In both therapy arms the increment of TV was significantly slower until day 85, max. uptake was lower only in one therapy arm (day 72-77 0.8 ± 0.23*105 vs. controls LT 78 1.2 ± 0.33 *105 Bq/ml). In this therapy arm overall survival was increased significantly (125d ± 8d vs. control 105 ± 11d). Conclusions F18-FDG-PET can monitor therapeutic efficacy of immunological tumor therapy in this autochthonous tumor model. Our data suggests adoptive T-cell transfer to be an efficient therapy with respect to survival as well as reducing tumor growth in this orthotopic gastric carcinoma. ER -